Results 1 to 10 of about 5,353 (220)

A woman with eptifibatide (integrilin)‐induced thrombocytopenia following treatment of a clot in her coronary artery: A case report and literature review [PDF]

Clinical Case Reports
Eptifibatide, a GPIIb/IIIa receptor inhibitor, has shown its efficacy and safety in patients with high clot burden in their coronary vessels. It is widely used in patients with this condition.
Morteza Safi, Roozbeh Nazari, Nahid Senobari, Homa Taheri, Pouya Ebrahimi   +4 more
doaj   +4 more sources

Protective effects of combined eptifibatide and ticagrelor in patients with unstable angina undergoing percutaneous coronary intervention: a single-center experience [PDF]

BMC Cardiovascular Disorders
Background We evaluated the safety and effectiveness of combined eptifibatide and ticagrelor in patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI).
Shangsong Shi, Zicheng Ling, Shaohua Gu, Tingbo Jiang, Lin Ling   +4 more
doaj   +4 more sources

Safety and Efficacy of Low-Dose Eptifibatide for Tandem Occlusions in Acute Ischemic Stroke [PDF]

Neurology International
Objectives: The optimal treatment strategy for ischemic stroke in patients presenting with tandem occlusions of the internal carotid artery remains controversial.
Paweł Latacz, Tadeusz Popiela, Paweł Brzegowy, Bartłomiej Lasocha, Krzysztof Kwiecień, Marian Simka   +5 more
doaj   +5 more sources

Acute Stent Thrombosis Associated with Eptifibatide-Induced Profound Thrombocytopenia [PDF]

Case Reports in Cardiology, 2020
Background. Eptifibatide is an inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that is commonly used in patients undergoing percutaneous coronary intervention (PCI). Case.
Amer Aljundi, Alaa Rahhal, Wafer Dabdoob
doaj   +3 more sources

Eptifibatide-induced acute profound thrombocytopenia in a patient with left main artery plaque rupture complicated by cardiogenic shock and gastrointestinal bleeding

Journal of Clinical and Preventive Cardiology, 2021
Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen and adhesion proteins such as fibronectin, vitronectin, and von Willebrand ...
Savvy Nandal, William Van Gaal, Francis A Ponnuthurai   +2 more
doaj   +3 more sources

Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background After a loading dose of ticagrelor, the rate of high on‐treatment platelet reactivity remains elevated, which increases periprocedural myocardial infarction and injury.
Moazez J. Marian, Hussein Abu Daya, Arka Chatterjee, Firas Al Solaiman, Mark F. Sasse, William S. Fonbah, Raymond W. Workman, Brittany E. Johnson, Sarah E. Carlson, Brigitta C. Brott, Sumanth D. Prabhu, Massoud A. Leesar   +11 more
doaj   +3 more sources

Addition of eptifibatide and manual thrombus aspiration to ticagrelor does not improve long-term survival after STEMI treated with primary PCI [PDF]

Frontiers in Pharmacology
Background: Current guidelines recommend that glycoprotein IIb/IIIa inhibitor (GPI) and manual aspiration thrombectomy should not be routinely used in patients with ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous ...
Paul-Adrian Călburean, Paul-Adrian Călburean, Paul Grebenișan, Ioana-Andreea Nistor, Krisztina Pal, Krisztina Pal, Victor Vacariu, Reka-Katalin Drincal, Alissa Anamaria Ion, István Adorján, Tiberiu Oltean, László Hadadi   +11 more
doaj   +3 more sources

Comparative Effects of Glenzocimab and Eptifibatide on Bleeding Severity in 2 Mouse Models of Intracranial Hemorrhage [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Antiplatelet drugs represent potential candidates for protecting the penumbral microcirculation during cerebral ischemia and improving the benefits of arterial recanalization in ischemic stroke.
Sébastien Dupont, Héloïse Lebas, Sabrina Mavouna, Eloïse Pascal, Astride Perrot, Adrien Cogo, Marie‐Charlotte Bourrienne, Carine Farkh, Mialitiana Solo Nomenjanahary, Véronique Ollivier, Fatima Zemali, Bernhard Nieswandt, Stéphane Loyau, Martine Jandrot‐Perrus, Eric Camerer, Jean‐Philippe Desilles, Mikael Mazighi, Yacine Boulaftali, Benoît Ho‐Tin‐Noé   +18 more
doaj   +3 more sources

Eptifibatide bolus dose postductal stenting intervention: A single-center experience [PDF]

Annals of Pediatric Cardiology
Objectives: Stent thrombosis, a potential complication of ductal stenting, is associated with high mortality. This is a catastrophic complication, which can occur acutely (within 24 h), subacutely (within 30 days), or late (≥30 days) after stent ...
Rishika Mehta, Amitabha Chattopadhyay, Aritra Mukherji, Sanjiban Ghosh, Jayita Nandy Das, Pushpanjali Gupta   +5 more
doaj   +3 more sources

Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention

The Egyptian Heart Journal, 2023
Background ST-segment elevation myocardial infarction (STEMI) is usually caused by a rupture in the atherosclerotic plaque, followed by platelet aggregation which ultimately leads to acute coronary artery occlusion.
Rozita Jalalian, Babak Bagheri, Jamshid Yazdani Charati, Shahrnaz Khalaghi, Mohammadreza Iranian, Mahsa Mohammadi   +5 more
doaj   +2 more sources